| Topic |
Speaker |
| National Research Program for Genomic Medicine Mechanisms of Metastasis and Progression of Lung Cancer |
Pan-Chyr Yang
(楊泮池) |
| Regulation of CRMP-1 by Protein Interaction Networks and Phosphorylation to Monitor the Completion of Cytokinesis in Lung Cancer Cells |
Chi-Ying F. Huang
(黃奇英) |
| Prognostic and Predictive Molecular Markers for Adjuvant Therapy in Early Stage NSCLC |
Ming-Sound Tsao |
| EGFR Mutations and Predictive Markers for EGFR TKI Therapy in Treatment of Non-small Cell Lung Cancer |
Tetsuya Mitsudomi |
| Ethnic Differences in the Treatment of Non-small Cell Lung Cancer with EGFR Tyrosine Kinase Inhibitors |
Masahiro Fukuoka |
| Outcomes of Curative Resection for Pathologic Stage I Non-small Cell Lung Cancer: A 20-year Analysis |
Wen-Hu Hsu
(許文虎) |
| Surgical Treatment for Multiple Primary Lung Cancer |
Yung-Chie Lee
(李元麒) |
| The Role of VATS in Lung Cancer Surgery |
Hui-Ping Liu
(劉會平) |
| Special Situation of Lung Cancer Surgery |
Ming-Ho Wu
(吳明和) |
| Reoperation for Lung Cancer: Experience with 31 Cases |
Nan-Yung Hsu
(許南榮) |
| The Trend of Application of the Molecular Biology in the Treatment Plan for Lung Cancer Patients |
Biing-Shiun Huang
(黃炳勳) |
| Innovative Clinical Trials for Non-small Cell Lung Cancer at NCC Korea |
Jin-Soo Lee |
| Non-small Cell Lung Cancer: Strategies to Change Natural Course of Disease and Improve Survival |
Alex Yuang-Chi Chang |
| Molecular Signatures of Non-small Cell Lung Cancer |
David P. Carbone |
| Patient Selection for EGFR Therapy |
Paul A. Bunn, Jr. |
| Treatment Strategy in Advanced NSCLC |
Paul A. Bunn, Jr. |
| Genome-wide Chromosomal Deletion and Promoter Hypermethylation and Their Clinical Implications in Lung Cancer |
Yi-Ching Wang
(王憶卿) |
| Chemosensitivity of Non-small Cell Lung Cancer Cells or Patients with Wild Type or Activated Mutation of Epidermal Growth Factor Receptors |
Chih-Hsin Yang
(楊志新) |
| Epigenetic Changes in Lung Cancer |
James Herman |
